EGenesis
Signal active
Organization
Contact Information
Overview
EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide.
About
Industries
Biotechnology, Life Science, Medical, Biopharma, Genetics
Founded
2014
Employees
101-250
Headquarters locations
Cambridge, Massachusetts, United States, North America
Social
Profile Resume
EGenesis headquartered in United States, North America, operates in the Biotechnology, Life Science, Medical, Biopharma, Genetics sector. The company focuses on Biotechnology and has secured $21.2B in funding across 80 round(s). With a team of 101-250 employees, EGenesis is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - EGenesis, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
0
Lead Investors
0
Total Funding Amount
$265.0M
Details
3
EGenesis has raised a total of $265.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 100.0M | ||
| 2021 | Late Stage Venture | 125.0M | ||
| 2017 | Early Stage Venture | 38.0M |
Investors
EGenesis is funded by 50 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Fan Ventures | - | FUNDING ROUND - Fan Ventures | 38.0M |
| JDRF T1D Fund | - | FUNDING ROUND - JDRF T1D Fund | 38.0M |
| EGenesis | - | FUNDING ROUND - EGenesis | 38.0M |
| E Squared Capital Management | - | FUNDING ROUND - E Squared Capital Management | 38.0M |
Recent Activity
News
Sep 23, 2024
Crunchbase News - Longevity Startups Are Getting Funding, But Not As Fast As We’re Aging
News
Sep 06, 2024
Crunchbase News - The Week’s 10 Biggest Funding Rounds: Safe Superintelligence Leads With Massive $1B Raise
News
Sep 05, 2024
Longevity.Technology - eGenesis lands $191m to advance xenotransplantation into clinical trials
News
Sep 04, 2024
Endpoints News - Transplant biotech eGenesis snags $191M after first use of gene-edited pig kidney
News
Sep 04, 2024
FinSMES - eGenesis Raises $191M in Series B Funding
News
Sep 04, 2024
Venture Capital Access Online - eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant